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Abstract
Cryptococcus neoformans is the most common cause of meningitis amongst adult Africans with HIV/AIDS. The widespread use of
fluconazole may lead to the emergence of isolates with reduced susceptibility. We studied C. neoformans isolates from HIV-infected
patients with cryptococcal meningitis. Genotyping and antifungal testing were performed to assess the genetic diversity, occurrence
of mixed infections and in vitro activity of antifungal agents. Isolates were recovered from cerebrospinal fluid prior to systemic
antifungal treatment. Six isolates were studied for each sample (a total of 114 isolates from 19 patients). Serotyping was performed
via LAC 1 and CAP 64 gene amplification and genotyping was performed using phage M13 core, (GACA)4 and (GTG)5 primers and
restriction polymorphism analysis of the URA5 gene. Susceptibilities for amphotericin B, flucytosine, fluconazole, voriconazole and
posaconazole were tested by the Sensititre YeastOne method. All strains were identified as C. neoformans var. grubii serotype
A. We identified nine major genotypes. Up to two genotypes were identified in the same sample. None of the isolates were
resistant to the studied drugs. However, 13 of 114 strains exhibited a reduced susceptibility to fluconazole and 13 of 114 strains
exhibited a reduced susceptibility to flucytosine. No correlation was found between the genotype and susceptibility. This study
confirms the prevalence of C. neoformans serotype A in Cameroon. Two genotypes may be responsible for a single episode of
cryptococcosis. The possibility of mixed infection and diminished susceptibility to fluconazole or flucytosine must be considered for
the management of cryptococcosis.
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Introduction
Cryptococcal meningitis is one of the most common life-
threatening opportunistic fungal infections in immunocom-
promised patients, particularly among those with AIDS in
sub-Saharan Africa [1]. Cryptococcus neoformans represents
the main microorganism that causes meningitis in African
adults with HIV/AIDS infection. [2]
Two distinct varieties of C. neoformans have been described
and are associated with three serotypes: C. neoformans var gru-
bii (serotype A), C. neoformans var neoformans (serotype D)
and AD hybrids [3]. C. gattii, another species of the genus Cryp-
tococcus, consists of serotypes B and C [3] and is also capable
of forming hybrids with C. neoformans [4]. Molecular typing
has resulted in the further subdivision of these two species
into eight major molecular types: VNI and VNII (serotype A;
var grubii), VNIII (serotype AD; var neoformans), VNIV (sero-
type D; var neoformans), VGI, VGII, VGIII and VGIV (serotypes
B and C; var gattii) [5]. Within C. neoformans var grubii, the
VNI molecular type is predominant worldwide [6].
Several molecular typing methods have been used in
the study of the epidemiology of C. neoformans. The most
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commonly used approaches involve amplified fragment length
polymorphism (AFLP) analysis, PCR fingerprinting and/or
PCR-restriction fragment length polymorphism (RFLP) analy-
sis, as well as mating and/or serotype-specific PCR [5,7,8].
Microsatellites are popular molecular typing targets because
they provide cost-effective genotyping with rapid turnaround
times and a high discriminatory power. Similar to multilocus
sequence typing (MLST) data, microsatellite typing data are
transportable and exchangeable between laboratories [9].
Differences in biology, epidemiology, pathogenicity, clinical
features and drug susceptibility have been associated with
species, varieties and molecular types in the genus Cryptococ-
cus [10,11]. Moreover, mixed infection by different molecular
types within a given patient has recently been reported [12].
Different treatment strategies are used in patients with
cryptococcal meningitis. Amphotericin B with or without flu-
cytosine remains the ‘reference standard’ antifungal for
induction therapy. A high oral dose of fluconazole with flucy-
tosine is not as effective as amphotericin B associated with
flucytosine [13]. In Cameroon, fluconazole is the most com-
monly administered drug for the treatment of cryptococco-
sis.
The objective of the present study was to determine the
existence and the occurrence of mixed Cryptococcus infec-
tions in HIV-positive patients from Cameroon. To achieve
this objective, we investigated the genetic diversity of six dif-
ferent isolates in a single sample for each patient using sev-
eral molecular typing methods. In addition, the in vitro
antifungal susceptibility of these different isolates was evalu-
ated for the improved management of cryptococcal disease
and investigation of potential antifungal drug resistance.
Materials and Methods
Yeast isolates
This study was a prospective study of 23 patients who exhib-
ited neuromeningeal symptoms with a suspicion of crypto-
coccosis. The patients included in the study were HIV
positive and hospitalized in the Hoˆpital Central, Yaounde´.
None of them received a systemic antifungal treatment prior
to the study. Cryptococcosis was diagnosed and confirmed
at the Laboratory of Microbiology and Hoˆpital de Jour, Hoˆpi-
tal Central, Yaounde, by positive India ink stains, cryptococ-
cal antigen latex agglutination slide tests (Crypto La-test
Fumouze Diagnostics, Levallois-Perret, France) in the
cerebrospinal fluid (CSF) and/or cultures associated with
urea-indole test. Only 19 of 23 samples exhibited a positive
culture for Cryptococcus for the CSFs collected from patients.
The average age was 38.1 years, with a range between 25
and 56 years. Cultures were encoded with the first letters
of patient’s last and first names. The identification of each
isolate after culturing was performed twice using a commer-
cial identification kit (ID32C, Biome´rieux). Each isolate was
stored on cryobeads as recommended by the manufacturer.
Six isolates were studied for each sample (five isolated colo-
nies from a culture plus the entire culture) for a total of 114
isolates from the 19 samples that yielded positive cultures.
This procedure was especially designed for the present
study. All isolates were culture-purified and grown for 3 days
on yeast extract potato dextrose agar prior to use.
Every patient included in this study was informed of the
risks and gave his or her consent. The present study
received the approval of the Cameroonian Human Investiga-
tions Committee and was supported by SIDACTION.
Susceptibility testing
The Sensititre antifungal susceptibility method was per-
formed according to the manufacturer’s instructions. A final
microorganism concentration of 1.5–8 · 103 CFU/mL was
recommended. The final inoculum in the broth was inocu-
lated onto YeastOne plates within 15 min. Twenty microli-
tres of the yeast suspension were transferred into 11 mL of
YeastOne inoculum broth. Plates containing serial two-fold
dilutions of the antifungal agents across 11 to 12 dilutions
were inoculated using the prepared inoculum and incubated
(35C, 48 h or 72 h). The minimal inhibitory concentration
(MIC) was recorded as the lowest concentration of antifun-
gal agents that prevented the development of a red colour.
Each test consisted of a microtitre plate, which contained
dried serial dilutions of the eight antifungal agents, posaco-
nazole (0.008–8 mg/L), amphotericin B (0.008–16 mg/L),
fluconazole (0.125–256 mg/L), itraconazole (0.008–16 mg/L),
ketoconazole (0.008–16 mg/L), flucytosine (0.03–64 mg/L),
voriconazole (0.008–16 mg/L) and caspofungin (0.008–16 mg/
L) in individual wells. The wells also contained a colorimetric
indicator, which improves the end point readability according
to a colour change from blue to purple. MICs for the Sensiti-
tre YeastOne assay were read after 48 h of incubation.
The Clinical and Laboratory Standards Institute M27-A3 pro-
tocol (CLSI M27-A3) was used for the MIC interpretative
guidelines [14–16]. The interpretive MIC criteria for fluco-
nazole were as follows: susceptible (S) £8 mg/L, susceptible-
dose-dependent (SDD) 16–32 mg/L and resistant
(R) ‡ 64 mg/L. The interpretive MIC criteria for flucytosine
were as follows: S £ 4 mg/L, intermediate (I) 8–16 mg/L and
R ‡ 32 mg/L. The interpretive MIC criterion for voriconazole
(S £ 1 mg/L) was based on the work of Pfaller et al. [17].
For Cryptococcus, interpretative criteria have not yet been
defined for posaconazole, amphotericin B, itraconazole and
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ketoconazole. Caspofungin is not active against Cryptococcus
and thus was not considered.
The test organisms included two American Type Culture
Collection (ATCC) strains that have been established as
quality control strains (Candida parapsilosis ATCC 22019 and
Candida krusei ATCC 6258) by the CLSI [14]. These isolates
were tested between 5 and 10 times, with ‡98% of the MICs
being within the reference ranges.
Geometric means MICs (G-MICs) were determined for
each drug that was tested (except for caspofungin, which is
not active against C. neoformans).
PCR fingerprinting
Primers for the minisatellite-specific core sequence of the
wild-type phage M13 (5¢-GAGGGTGGCGGTTCT-3¢) and
the microsatellite-specific sequences (GTG)5 and (GACA)4
were used as single primers in the PCR procedure, as
described by Meyer et al. [10] Briefly, the amplifications were
performed in a final volume of 50 lL containing 40.5 lL of
sterile deionised water, 50 ng of DNA, 5 lL of 1· PCR buf-
fer (10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl2
and 0.01% gelatine) (Sigma-Aldrich, Saint-Quentin-Fallavier,
France), 0.2 mM of each dNTP, (Sigma-Aldrich, Fr), 20 lM
primer and 2.5 U Taq DNA Polymerase from Thermus aquati-
cus (Sigma-Aldrich). Each PCR was performed in a Primus 96
plus (MWG AG Biotech, Ebersberg, Germany) thermal
cycler, using the following conditions.
M13 and (GTG)5: initial denaturation (94C, 3 min), 40
cycles of denaturation (94C, 30 s), annealing (50C, 1 min)
and extension (72C, 1.5 min) and a final extension step at
72C for 6 min.
-(GACA)4: the microsatellite-specific primer (GACA)4 (5¢ GA
CAGACAGACAGACA 3¢) was used as the only primer in the
PCR reactions [18]. The amplification conditions were as
follows: initial denaturation (94C, 3 min), 40 cycles of dena-
turation (94C, 30 s), annealing (40C, 1 min) and extension
(72C, 1.5 min) and a final extension step at 72C for 7 min.
Amplification products were separated by electrophoresis in
a 6% Poly(NAT) Wide Mini S-2·25 gel (Elchrom Scientific,
Ebersberg, Germany) in 1· Tris-acetate EDTA buffer at
10 V/cm for 105 min. The bands were visualized under UV
light. A 100 bp molecular-size marker (Promega, Ebersberg,
Germany) was loaded in each gel as a control.
URA5 RFLP analysis: PCRs were performed with the primers
URA5 (5¢-ATGTCCTCCCAAGCCCTCGACTCCG-3¢) and
SJ01 (5¢-TAAGACCTCTGAACACCGTACTC-3¢) [7]. The
reaction conditions were as follows: initial denaturation
(94C, 2 min), 35 cycles of denaturation (94C, 45 s), anneal-
ing (61C, 1 min), extension (72C, 2 min) and a final exten-
sion cycle at 72C for 10 min.
Fifteen microlitres of PCR products were double digested
with Sau96I (10 U/ml) and HhaI (20 U/ml) for 5 h at 37C.
The digested fragments were separated on 1.5% agarose gels
stained with ethidium bromide.
Serotyping by multiplex PCR
Four primers designed for cloning LAC1 and a pair of prim-
ers for CAP64 were used (Table 1). The primers for CAP64
were based on DNA sequences reported by Ito-Kuwa et al.
[19]. The primers for LAC1 and CAP64 were prepared at a
concentration of 10 lM. For PCRs with the simultaneous
use of the six primers for LAC1 and CAP64, 1.65 lL of each
LAC1 primer and 0.85 lL of each CAP64 primer were
added to a 50 lL reaction mixture. The PCR amplification
was initiated at 94C for 3 min, followed by 35–40 cycles of
denaturation (94C, 30 s), annealing (47C, 60 s) and poly-
merization (72C, 1.5 min), and a final extended polymeriza-
tion step (72C, 7 min). The amplified products were run at
100 V for 20 min on 1.5% agarose gels stained with ethidium
bromide.
The molecular profiles obtained by PCR fingerprinting were
analysed based on the presence or absence of readily appar-
ent and well-defined bands in the digitised gel images. The
molecular types were assigned by comparison with the refer-
ence strains (ATCC MYA-4564, ATCC MYA-4565, ATCC
MYA-4566, ATCC MYA-4567) for VNI to VNIV. A dendro-
gram based on genotypic data was generated using the UP-
GMA algorithm.
Results
Table 2 summarizes the in vitro susceptibility data of 114 iso-
lates of Cryptococcus to posaconazole, amphotericin B, fluco-
nazole, itraconazole, ketoconazole, flucytosine and
voriconazole as determined using the Sensititre YeastOne
assay. Caspofungin results are not presented in this table
because this drug is inactive against C. neoformans.
TABLE 1. Primers used for LAC1 and CAP64 amplification
Primer sequences
LAC1 1 5¢-GGAACAGCAACCACACTACTG-3¢
2 5¢-CATATTGGGTGGCATCTTACTGAGGGA-3¢
3 5¢-CCAGGGAACATGTTGTTGAC-3¢
4 5¢-GTTGTGGAAGGCAAAGAAAC-3¢
CAP64 1 5¢-GCCAAGGGAGTCTTATATGG- 3¢
2 5¢-GCAAAGGGTTCACCAAATCG- 3¢
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All isolates exhibited low MIC to posaconazole, amphoter-
icin B, itraconazole, ketoconazole and voriconazole. As
expected, all isolates exhibited high MIC to caspofungin. The
lowest MIC values were observed for voriconazole, with
MIC50 and MIC90 values of 0.015 and 0.12 mg/L, respectively.
High MIC values were determined for fluconazole (MIC50
and MIC90 values of 2 and 16 mg/L, respectively) and flucyto-
sine (MIC50 and MIC90 values of 2 and 8 mg/L, respectively).
The G-MICs ranged from 0.06 mg/L for voriconazole to
3.22 mg/L for fluconazole.
When considering each isolate, 13/114 (11%) were catego-
rized as SDD for fluconazole and I for flucytosine. Five of 19
patients studied exhibited isolates with different MIC catego-
ries for fluconazole in the same sample. Seven of 19 patients
exhibited isolates with different MIC categories for flucytosine
in the same sample. Briefly, patients ELOGA, BAY, BAI, LONG
and KEH exhibited isolates that were both S and SDD for
fluconazole in the same sample and patients ELOGA, BEL,
OVA, BAY, MYA, BEL INN and KEH exhibited isolates that
were both S and I for flucytosine in the same sample.
Genotyping
All isolates were identified as Cryptococcus neoformans var.
grubii (serotype A) (Fig. 1). Despite the high discriminatory
power, the analysis of the PCR patterns did not allow for
the detection of the variability between both strains based
on URA5 fragment length polymorphism and phage M13
core sequence primer amplification. These methods gener-
ated VNI profiles for all the studied isolates. (GACA)4 asso-
ciated with (GTG)5 generated 20 different genotypes
grouped into nine major molecular types (i.e. genotypes with
>95% of similarity) for the 114 studied isolates. Eight patients
exhibited C. neoformans with two different major molecular
types in the same sample.
Discussion
The in vitro activity results for the main antifungal drugs are
comparable with previously published values [12]. Neverthe-
less, the MIC90 values for fluconazole and flucytosine were
greater in the present work than in previous studies [20],
although one prior study identified a strain resistant to flucyto-
sine [21]. As previously suggested, the extensive use of fluco-
nazole could explain the elevated MICs observed in this study
[22]. However, previous reports have already demonstrated
the low activity of this drug against C. neoformans even though
fluconazole has been proven to be active in vitro [23].
The present work demonstrated for the first time that at
least two isolates with different antifungal susceptibilities (i.e.
with a 3- to 4-fold difference in the MICs) can be found in a
single sample despite the lack of antifungal treatment admin-
istered to the patients prior to the study. Although resis-
tance was not observed in the present collection of isolates,
these results may imply the presence of potentially resistant
isolates in a given sample.
As demonstrated in previous studies, where C. neofor-
mans var. grubii (serotype A) was the most common causa-
tive agent isolated from patients with cryptococcosis in sub-
Saharan Africa, all of the patients studied in the Hoˆpital
TABLE 2. Minimum inhibitory concentration of the 114 C. neoformans strains tested for seven antifungal drugs determined by
the Sensititre YeastOne microdilution method
Posaconazolea Amphotericin Ba Fluconazolea Itraconazolea Ketoconazolea Flucytosinea Voriconazolea
Sampleb Rangec (mg/L)
ELOGA 0.03–0.5 0.25–0.5 1–16 0.015–0.12 0.015–0.25 1–16 0.015–0.12
BAY 0.06–0.5 0.12–0.25 2–16 0.03–0.12 0.015–0.12 2–8 0.03–0.12
BEL 0.03–0.25 0.12–0.5 2–8 <0.008–0.06 <0.008–0.12 2–8 <0.008–0.06
MYA 0.06–0.25 0.06–1 2–8 0.015–0.12 0.015–0.12 1–8 0.015–0.12
BEL INN 0.06–0.25 0.12–0.25 0.5–8 0.015–0.06 0.015–0.06 1–8 <0.008–0.06
IRO 0.06–0.25 0.06–0.5 1–8 0.015–0.06 0.015–0.06 1–16 <0.008–0.06
LON 0.008–0.5 0.06–0.25 1–16 0.015–0.12 0.015–0.12 2–4 0.015–0.12
KEH 0.06–0.5 0.12–0.25 2–16 0.015–0.12 <0.008–0.12 2–8 <0.008–0.12
BAI 0.06–0.5 0.06–0.25 2–32 0.03–0.12 0.015–0.12 4 0.03–0.12
ADJ 0.06 0.5 2–4 0.03–0.06 0.015–0.03 0.5–2 0.03
OVA 0.06 0.5 2–4 0.03–0.06 0.015 2–8 0.015
NYA 0.03–0.06 0.5 2 0.015–0.03 <0.008–0.015 2–4 <0.008–0.015
NDO 0.03–0.06 0.25–0.5 1–2 0.015–0.03 <0.008–0.008 1–2 <0.008–0.015
BAH 0.008–0.015 0.25–0.5 0.5–1 <0.008 <0.008 2–4 <0.008
NGO 0.03–0.06 0.5 1–2 0.015–0.03 <0.008–0.008 2–4 <0.008–0.008
SER 0.03–0.06 0.5 2 0.03 0.008–0.015 0.5–2 <0.008–0.015
KEN 0.015–0.06 0.25–0.5 2 0.015–0.03 <0.008–0.015 1–4 0.015
NJO 0.03–0.06 0.25–0.5 2 0.015 0.015 2 0.015
MFO 0.06–0.12 0.25–0.5 2–4 0.015–0.06 0.008–0.015 1–2 0.015–0.03
G MICc 0.10 0.31 3.22 0.05 0.08 2.76 0.06
aPatients for whom between-strain differences in antifungal susceptibility were of three dilutions or larger figure in bold.
bOriginal sample +5 colonies.
cGeometric minimal inhibitory concentration.
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Genus Species Experiment Patient Clone
Cryptococcus neoformans  BEL INN clone 1
Cryptococcus neoformans  BEL INN clone 3
Cryptococcus neoformans  ELOGA clone 4
Cryptococcus neoformans  KEH clone 1
Cryptococcus neoformans  KEH clone 2
Cryptococcus neoformans  KEH clone 3
Cryptococcus neoformans  KEH clone 4
Cryptococcus neoformans  ADJ original sample
Cryptococcus neoformans  ELOGA clone 3
Cryptococcus neoformans  NGO original sample
Cryptococcus neoformans  SER clone 3
Cryptococcus neoformans  SER clone 4
Cryptococcus neoformans  SER clone 5
Cryptococcus neoformans  BEL INN original sample
Cryptococcus neoformans  MYA original sample
Cryptococcus neoformans  BEL INN clone 2
Cryptococcus neoformans  BEL INN clone 4
Cryptococcus neoformans  BEL INN clone 5
Cryptococcus neoformans  KEH original sample
Cryptococcus neoformans  BEL clone 5
Cryptococcus neoformans  ELOGA original sample
Cryptococcus neoformans  IROCHA original sample
Cryptococcus neoformans  IROCHA clone 1
Cryptococcus neoformans  MYA clone 3
Cryptococcus neoformans  MYA clone 4
Cryptococcus neoformans  BEL clone 1
Cryptococcus neoformans  BEL clone 2
Cryptococcus neoformans  BEL clone 3
Cryptococcus neoformans  BEL clone 4
Cryptococcus neoformans  IROCHA clone 3
Cryptococcus neoformans  IROCHA clone 4
Cryptococcus neoformans  IROCHA clone 5
Cryptococcus neoformans  IROCHA clone 2
Cryptococcus neoformans  ELOGA clone 1
Cryptococcus neoformans  ELOGA clone 2
Cryptococcus neoformans  MYA clone 1
Cryptococcus neoformans  MYA clone 2
Cryptococcus neoformans  BAY clone 4
Cryptococcus neoformans  BAY clone 5
Cryptococcus neoformans  BAY original sample
Cryptococcus neoformans  BAY clone 1
Cryptococcus neoformans  BAY clone 2
Cryptococcus neoformans  BAY clone 3
Cryptococcus neoformans  KEH clone 5
Cryptococcus neoformans  SER clone 1
Cryptococcus neoformans  SER clone 2
Cryptococcus neoformans  ADJ clone 1
Cryptococcus neoformans  ADJ clone 2
Cryptococcus neoformans  ADJ clone 3
Cryptococcus neoformans  ADJ clone 4
Cryptococcus neoformans  ADJ clone 5
Cryptococcus neoformans  ELOGA clone 5
Cryptococcus neoformans  LONG clone 1
Cryptococcus neoformans  LONG clone 2
Cryptococcus neoformans  LONG clone 3
Cryptococcus neoformans  LONG clone 4
Cryptococcus neoformans  LONG clone 5
Cryptococcus neoformans  LONG original sample
Cryptococcus neoformans  MYA clone 5
Cryptococcus neoformans  SER original sample
Cryptococcus neoformans  NGO clone 3
Cryptococcus neoformans  NGO clone 4
Cryptococcus neoformans  NGO clone 5
Cryptococcus neoformans  NGO clone 1
Cryptococcus neoformans  NGO clone 2
Cryptococcus neoformans  BAI clone 4
Cryptococcus neoformans  BAI clone 5
Cryptococcus neoformans  BAI original sample
Cryptococcus neoformans  BAI clone 1
Cryptococcus neoformans  BAI clone 2
Cryptococcus neoformans  BAI clone 3
Cryptococcus neoformans  MFO clone 5
Cryptococcus neoformans  MFO original sample
Cryptococcus neoformans  MFO clone 1
Cryptococcus neoformans  MFO clone 2
Cryptococcus neoformans  MFO clone 3
Cryptococcus neoformans  MFO clone 4
Cryptococcus neoformans  NJO clone 4
Cryptococcus neoformans  NJO clone 5
Cryptococcus neoformans  NDO clone 4
Cryptococcus neoformans  NDO clone 5
Cryptococcus neoformans  NDO original sample
Cryptococcus neoformans  NDO clone 1
Cryptococcus neoformans  NDO clone 2
Cryptococcus neoformans  NDO clone 3
Cryptococcus neoformans  OVA clone 4
Cryptococcus neoformans  OVA clone 1
Cryptococcus neoformans  OVA clone 3
Cryptococcus neoformans  OVA clone 5
Cryptococcus neoformans  OVA original sample
Cryptococcus neoformans  OVA clone 2
Cryptococcus neoformans  BAH clone 5
Cryptococcus neoformans  NYA clone 2
Cryptococcus neoformans  NYA clone 3
Cryptococcus neoformans  BAH clone 4
Cryptococcus neoformans  NYA original sample
Cryptococcus neoformans  NYA clone 1
Cryptococcus neoformans  BAH original sample
Cryptococcus neoformans  BAH clone 1
Cryptococcus neoformans  NYA clone 4
Cryptococcus neoformans  NYA clone 5
Cryptococcus neoformans  BAH clone 2
Cryptococcus neoformans  BAH clone 3
Cryptococcus neoformans  NJO original sample
Cryptococcus neoformans  NJO clone 1
Cryptococcus neoformans  NJO clone 2
Cryptococcus neoformans  NJO clone 3
Cryptococcus neoformans  KEN original sample
Cryptococcus neoformans  KEN clone 1
Cryptococcus neoformans  KEN clone 2
Cryptococcus neoformans  KEN clone 3
Cryptococcus neoformans  KEN clone 4
Cryptococcus neoformans  KEN clone 5
Cryptococcus neoformans  BEL original sample
10098979594929189888685
FIG. 1. Relationship between the obtained genotypes from the 19 patients studied. Genotype data were generated by URA5 gene RFLP and
micro- and minisatellite polymorphism. The dendrogram obtained is based on UPGMA clustering. The scale bar indicates the percentage of simi-
larity. Each major group was determined when percentage was >95% of similarity. Braces determine major molecular types.
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Central of Yaounde, Cameroon, exhibited C. neoformans
with serotype A [24]. Moreover, Dromer et al. [25] demon-
strated that cryptococcal infections with serotype A strains
exhibited a higher mortality rate than other serotypes even
after treatment. Surprisingly the URA5 RFLP and M13 prim-
ers used here did not exhibit the expected high extent of
polymorphism between isolates [7,8,11,12]. The molecular
types obtained were comparable with those described for
VNI [10,11]. This result is in agreement with serotyping
results because all C. neoformans var. grubii belong to the
VNI molecular type [12,26]. Microsatellite polymorphism
revealed nine major molecular types and eight patients
exhibited at least two different molecular types. This has
already been shown for aspergillosis and candidiasis [27,28].
Evidence of mixed infections was previously reported by Ill-
nait Zaragozi et al. in a recent study of serial Cryptococcus
isolates from Cuban patients [12]. Moreover, a study by
Desnos-Ollivier et al. [29] recently reported a high fre-
quency of mixed infections in 20% of patients with crypto-
coccal disease. The results of the present study are in
agreement with this paper because 42% of our patients
exhibited two different molecular type. Nevertheless,
although a correlation between high MIC values and strain
genotype has recently been demonstrated [30], such a rela-
tionship was not found in the present study. As suggested
by Illnait-Zaragozi et al. [12], these genotypic differences
occur due to a microevolution of the original strain. How-
ever, the present study demonstrated that the within-host
Cryptococcus are heterogeneous (i) genotypically and (ii) with
regard to their antifungal susceptibility. This has never been
demonstrated in Cameroon and the present study provides
new data for a better understanding of the biology and the
epidemiology of C. neoformans.
Conclusion
Cryptococcosis remains one of the most life threatening oppor-
tunistic infections in HIV-positive patients in Africa. The present
study analysed the ‘within-host’ diversity of Cryptococcus. The
results demonstrated the high genetic variability among clinical
isolates and the presence of isolates with different MICs in a
given sample. A larger study with sequential isolates should be
conducted to confirm these results and the clinical implications
of these findings require further investigation.
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